It is tempting to speculate that a secondary effect of pharmacological STAT3 inhibition in cancer therapy may consist in a reduction of IL-15 dependent HIF-1α enrichment in NK cells, which may be expected to improve NK cell anti-tumor activity (12, 13). Here, HIF1A is linked to cancer.